Of course, my valuation was back in early 2013, pre-Brilacidin - so double it?

rule_rationale Saturday, 01/26/13 05:12:24 PM
Re: None
Post # of 65442
Since we're all speculating - here are my scary numbers:

first look here for industry values

http://pages.stern.nyu.edu/~adamodar/New_Home...sdata.html

Biotech Price per Revenue per Share (P/S) is 6.01 average as of Jan 2013.

Now we must make a BIG assumption, but lets make that assumption of revenue for curing cancer,psoriasis,etc. to be equal to $20B annually. We also must assume the fully diluted share count, let's say about 150M - I think everyone can agree that is close from prior discussions.

Now for the math:

6.01 = pps/(Revenue/Outstanding shares), or pps= 6.01*Revenue/Outstanding shares

pps=6.01*$20B/150M= $801.33

Now that is far in the future if Cellceutix were to get all the way through studies and then take market share, and develope to $20 Billion in Revenue... it could happen...

$800 WOW

Let me know if there are any gross errors in there.